Research programme: transient receptor potential channel inhibitors - Boehringer Ingelheim/Hydra Biosciences

Drug Profile

Research programme: transient receptor potential channel inhibitors - Boehringer Ingelheim/Hydra Biosciences

Latest Information Update: 15 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim; Hydra Biosciences
  • Class Small molecules
  • Mechanism of Action TRPC4 cation channel inhibitors; TRPC5 cation channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research CNS disorders; Kidney disorders

Most Recent Events

  • 13 Apr 2015 Early research in Kidney disorders in USA and Germany (unspecified route)
  • 13 Apr 2015 Hydra Biociences and Boehringer Ingelheim agree to co-develop transient receptor potential cation channel (C4/5) inhibitors in USA and Germany for renal failure and kidney disorders
  • 24 Apr 2014 Early research in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top